Photo via Fast Company
In a significant reversal of decades-long drug policy, the FDA has granted expedited review status to three experimental psychedelic compounds designed to treat severe mental health conditions. According to Fast Company, two of the fast-tracked drugs will focus on psilocybin as a treatment for depression, while a third will study methylone for post-traumatic stress disorder. The expedited review process compresses the standard 10-to-12-month FDA approval timeline to just one to two months, meaning these treatments could become available as early as this summer.
The accelerated approval comes on the heels of a presidential executive order directing the FDA to streamline the review process for psychedelic drugs receiving "breakthrough therapy" designations. FDA Commissioner Marty Makary emphasized that psychedelics have potential to address the nation's mental health crisis, including treatment-resistant depression, alcoholism, and substance abuse conditions. This represents part of a broader administrative shift toward reclassifying controlled substances, including efforts to move marijuana from Schedule I to Schedule III status.
The expedited review is enabled through the Commissioner's National Priority Voucher (CNPV) program, launched in June 2025. The program allows pharmaceutical companies to submit significant portions of drug applications before clinical trials conclude, theoretically reducing inefficiencies and bringing treatments to market faster. However, the program has drawn criticism for launching without Congressional approval and raising concerns about potential conflicts of interest between pharmaceutical companies and the administration.
Mental health experts urge caution despite enthusiasm for accelerated approval timelines. Dr. Peg Nopoulos, chair of the University of Iowa's psychiatry department, stressed to NBC News that rigorous scientific validation remains essential, regardless of expedited pathways. Researchers emphasize the need to understand which patient populations benefit most from these treatments, identify potential risks, and ensure that faster approval does not compromise the integrity of clinical safety data.
